Methimazole Dosing Based on Free T4 Elevation
For mild hyperthyroidism (free T4 < 3 × upper limit of normal), start methimazole 10–20 mg once daily; for moderate-to-severe hyperthyroidism (free T4 ≥ 3 × upper limit of normal), start 30–40 mg once daily. 1
Initial Dosing Algorithm by FT4 Level
Mild Hyperthyroidism (FT4 < 3 × ULN)
- Start methimazole 15–20 mg once daily (equivalent to carbimazole 15–20 mg daily). 1
- The FDA label recommends 15 mg daily for mild hyperthyroidism, divided into three doses, though once-daily dosing is now preferred. 2
- Higher initial doses in this group do not shorten time to euthyroidism and increase the risk of iatrogenic hypothyroidism. 1
Moderate-to-Severe Hyperthyroidism (FT4 ≥ 3 × ULN)
- Start methimazole 30–40 mg once daily (equivalent to carbimazole 30–40 mg daily). 1
- The FDA label recommends 30–40 mg daily for moderately severe hyperthyroidism. 2
- A 20 mg daily dose is inadequate for this severity; most patients remain thyrotoxic after 4 weeks, prolonging cardiovascular risk. 1
Severe Hyperthyroidism (FT4 ≥ 2–3 × ULN with Cardiovascular Manifestations)
- Start methimazole 40–60 mg once daily for extremely severe cases. 1
- The FDA label permits up to 60 mg daily for severe hyperthyroidism. 2
- Always add beta-adrenergic blockade in patients > 60 years, with resting heart rate > 90 bpm, or with known cardiovascular disease. 1, 3
- This maximum dose should be reduced by approximately 50% once euthyroidism is achieved (typically within 4–8 weeks). 1
Dose Titration After Initial Control
Week 4 Assessment
- Measure free T4 and total T3 (TSH remains suppressed and unreliable at this stage). 1, 3
- If free T4 has normalized or is low-normal, reduce the dose by 50% (e.g., 30 mg → 15 mg). 1
- If free T4 is still elevated but has fallen substantially, maintain the current dose and retest in 4 weeks. 1
- If free T4 shows minimal change, verify adherence and consider a dose increase. 1
Maintenance Phase (Weeks 8–18)
- Typical maintenance dose: 5–15 mg methimazole daily (equivalent to 5–10 mg carbimazole). 1
- Continue monitoring every 4–8 weeks until euthyroid on the minimal effective dose. 3
- Once euthyroid, monitor every 2–3 months for the remainder of the 12–18-month treatment course. 1, 3
Target Thyroid Levels During Treatment
- Target free T4 at or slightly above the upper limit of normal while TSH remains suppressed; this pattern does not indicate treatment failure. 1, 3
- Persistently suppressed TSH with normal free T4 is expected for weeks to months after normalization and should not prompt dose reduction. 1, 3
- Attempting to normalize TSH during active treatment can cause iatrogenic hypothyroidism and worsen Graves' orbitopathy. 1
Critical Pitfalls to Avoid
- Do not use 20 mg methimazole as the initial dose when FT4 exceeds 3–4 × ULN; this leaves most patients thyrotoxic after 4 weeks. 1
- Do not maintain high initial doses (30–60 mg) after euthyroidism is reached; failure to reduce the dose causes iatrogenic hypothyroidism. 1
- Do not rely on TSH for dose adjustment during the first 3 months; use free T4 and total T3 as primary parameters. 1
- Do not discontinue methimazole before 12 months unless definitive therapy (radioiodine or thyroidectomy) is planned; premature cessation markedly increases relapse risk. 1
Special Populations
Pregnancy
- First trimester: Switch immediately to propylthiouracil because methimazole is associated with congenital malformations. 1, 4
- Second and third trimesters: Switch back to methimazole to avoid propylthiouracil-related hepatotoxicity. 1, 4
- Monitor thyroid function monthly and adjust dose to keep free T4 at or slightly above the non-pregnant reference range. 1, 4
Elderly or Cardiovascular Comorbidities
- In elderly patients or those with cardiovascular disease, a lower initial dose of 10–20 mg daily is advised to avoid rapid hormone fluctuations. 1
- Beta-blockade should always be added when starting methimazole therapy in this population. 1, 3